Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7428731 |
Synonyms | |
Therapy Description |
RO7428731 is a bispecific antibody that targets EGFR variant III (EGFRvIII) and CD3, resulting in cross-linking of tumor cells and cytotoxic T-lymphocytes, and potentially leading to increased killing of EGFRvIII-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7428731 | RO-7428731|RO 7428731 | CD3 Antibody 99 | RO7428731 is a bispecific antibody that targets EGFR variant III (EGFRvIII) and CD3, resulting in cross-linking of tumor cells and cytotoxic T-lymphocytes, and potentially leading to increased killing of EGFRvIII-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05187624 | Phase I | RO7428731 | A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma | Active, not recruiting | USA | NLD | ESP | DNK | CAN | AUS | 0 |